

## Stability of methylation markers in head and neck squamous cell carcinoma

Shama Virani, PhD,<sup>1</sup> Emily Light, MS,<sup>2</sup> Lisa A. Peterson, MPH,<sup>3</sup> Maureen A. Sartor, PhD,<sup>4</sup> Jeremy M. G. Taylor, PhD,<sup>2</sup> Jonathan B. McHugh, MD,<sup>5</sup> Gregory T. Wolf, MD,<sup>3</sup> Laura S. Rozek, PhD<sup>1,3\*</sup> and Investigators of the University of Michigan Head and Neck Specialized Programs of Research Excellence (SPORE) Program<sup>3</sup>

<sup>1</sup>Department of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan, <sup>2</sup>Department of Biostatistics, University of Michigan, School of Public Health, Ann Arbor, Michigan, <sup>3</sup>Department of Otolaryngology–Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, <sup>4</sup>Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, Michigan, <sup>5</sup>Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.

Accepted 20 July 2015

Published online 13 November 2015 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/hed.24223

**ABSTRACT:** *Background.* As cancer progresses, methylation patterns change to promote the tumorigenic phenotype. However, stability of methylation markers over time and the extent that biopsy samples are representative of larger tumor specimens are unknown. This information is critical for clinical use of such biomarkers.

*Methods.* Ninety-eight patients with tumor specimens from 2 timepoints were measured for DNA methylation in the promoter regions across 4 genes.

*Results.* There were no significant differences in overall methylation of *CCNA1* (cyclin A1), *NDN* (necdin), deleted in colorectal carcinoma (*DCC*), and cluster of differentiation 1a (*CD1A*) within paired specimens ( $p$  values = .56, .17, .66, and .58, respectively). All genes showed

strong correlations between paired specimens across time. Methylation was most consistent for *CCNA1* and *NDN* over time.

*Conclusion.* This report provides the first evidence that methylation markers measured in biopsy samples are representative of gene methylation in later specimens and suggests that biopsy markers could be representative biomarkers for use in defining personalized treatment utilizing epigenetic changes. © 2015 Wiley Periodicals, *Head Neck* 38: E1325–E1331, 2016

**KEY WORDS:** DNA methylation, head and neck cancer, stability, time, tumor

## INTRODUCTION

There is a growing body of literature showing associations between molecular markers and head and neck cancer. These markers are being developed as potential clinical tools to direct treatment, identify low-risk patients who may benefit from less harsh treatments, and predict prognosis. The use of epigenetic markers is a promising tool in this regard. These markers do not change the sequence of DNA, may be reversible, and are indicative of tumor biology.<sup>1</sup> Specifically, variation in DNA methylation is one of the hallmark processes of cancer and, potentially, these markers might be used as therapeutic targets alone, or to select patients for more effective therapy. For example, gene promoter hypermethylation of the DNA repair gene, *MGMT*, is a prognostic marker for glioma patients and is currently being evaluated as a marker

for patient selection for carmustine and temozolomide in clinical trials.<sup>1,2</sup> Methylation of the mismatch repair gene, *hMLH1*, was found to significantly increase upon relapse of patients with epithelial ovarian cancer and was associated with poor survival.<sup>3</sup> Hypermethylation of a DNA helicase gene involved in DNA replication, recombination and DNA repair, *WRN*, increases sensitivity of colorectal tumors to topoisomerase inhibitors. Combined therapy with DNA damaging agents showed significantly better prognosis in patients with hypermethylated *WRN* than in patients with unmethylated *WRN*.<sup>4</sup> Such markers offer high translatability into the clinical setting and can allow for personalized therapy with high efficacy depending upon the methylation profile of a patient's tumor.

An inherent limitation of incorporating methylation markers clinically is that the persistence of methylation in a tumor is unknown. As cancer progresses, methylation patterns can change to promote the tumor phenotype.<sup>5,6</sup> Further, methylation of specific genes could differ significantly depending on timing and site of tumor sampling. However, methylation markers that are known to persist over time may potentially be used to direct treatment. Whether biopsy specimens would be representative of samples obtained at surgical resection is particularly important in head and neck cancer in which nonsurgical primary treatment is becoming more common. This report addresses this important limitation and provides evidence

\*Corresponding author: L. Rozek, Department of Environmental Health Sciences, University of Michigan School of Public Health, 1415 Washington Heights, 6630 SPH, Ann Arbor, MI 48109-2029. E-mail: rosek@umich.edu

Contract grant sponsor: Federal funds from the National Institutes of Health/National Cancer Institute (NIH/NCI) under the University of Michigan Specialized Programs of Research Excellence (SPORE) grant P50CA097248, as well as through NIH/NCI R01CA158286.

Additional Supporting Information may be found in the online version of this article.

that tumor biopsy specimens can be used to promote the development of epigenetically based treatments for cancer in a clinical setting. Here, we measure the methylation of four genes across time: *CCNA1* (cyclin A1), *NDN* (necdin), deleted in colorectal carcinoma (*DCC*), and cluster of differentiation 1a (*CD1A*). A discovery-based study previously published by our group was designed to identify novel prognostic epigenetic biomarkers for patients with head and neck squamous cell carcinoma (HNSCC).<sup>7,8</sup> *CCNA1* was found to be differentially methylated by human papillomavirus (HPV) status.<sup>7</sup> *NDN* and *CD1A* were also differentially methylated in this discovery analysis, however, they were not significant, potentially because of small sample size. *NDN* is an imprinted gene previously implicated in epithelial ovarian, bladder, breast, colorectal, and urothelial cancers, as well as premalignant lesions, such as vulval intraepithelial neoplasia and Barrett's esophagus, although it has not been studied in the context of HNSCC.<sup>7-14</sup> *CD1A* was the first immune gene found to be differentially methylated in the discovery analysis. *CD1A* methylation has not been previously studied in HNSCC, however, significant hypermethylation of *CD1B*, *CD1C*, *CD1D1*, and *CD1E* has been found in HPV-positive HNSCC tumors compared with HPV-negative tumors.<sup>15</sup> Deleted in colorectal carcinoma (*DCC*) and *CCNA1* was previously found to be hypermethylated in HNSCC and were chosen for its role as a tumor suppressor and involvement with HPV.<sup>16-20</sup> Previous literature on the importance of these genes in HNSCC highlights their potential clinical relevance. However, validation of their methylation stability across time is critical in determining the clinical utility of these epigenetic biomarkers.

## MATERIALS AND METHODS

### Study population

This study takes advantage of an established cohort of patients with head and neck cancer from the University of Michigan Head and Neck Cancer Specialized Program of Research Excellence (SPORE). Details on the cohort can be found in a separate study.<sup>21</sup> Eligible subjects were biopsied pretreatment and diagnosed with head and neck squamous cell carcinoma at an outside hospital before referral to the University of Michigan for treatment. Upon presentation at the University of Michigan, patients may be rebiopsied and staged during treatment planning. Ninety-eight subjects who signed a written, informed consent, had both a formalin-fixed paraffin-embedded (FFPE) biopsy specimen from an outside hospital and a surgical resection ( $n = 70$ ) or biopsy ( $n = 28$ ) specimen from the University of Michigan at a second timepoint available for microdissection and methylation analysis. Histology was confirmed on all samples by a qualified pathologist (J. B. M.). Areas of >70% tumor cellularity were specified for use in microdissection. Subjects completed an epidemiological questionnaire of behavioral and pathophysiological information. This study was approved as being within the ethical standards of the Institutional Review Board of the University of Michigan.

### Microdissection/DNA extraction/bisulfite conversion/human papillomavirus testing

Designated areas of FFPE tissue were microdissected from unstained slides and DNA was extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA), in accord with the manufacturer's protocol. DNA concentration was measured with a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA). Sodium bisulfite treatment was performed on 250 ng of DNA using the Epitect Bisulfite Kit (Qiagen), in accord with the manufacturer's recommended protocol. HPV status was determined by an ultrasensitive method using real-time competitive polymerase chain reaction (PCR) and matrix-assisted laser desorption/ionization mass spectrometry, as described and validated previously, because of its low DNA input requirement and rapid identification of HPV types, with high sensitivity and specificity.<sup>18,22-25</sup>

### Methylation analysis

Methylation assays for promoter regions of *DCC*, *CD1A*, and *NDN*, were designed using PyroMark Assay Design 2.0 software and conducted via pyrosequencing across 5, 2, and 3 CpG sites, respectively (Qiagen). The promoter region of *CCNA1* was sequenced across 4 CpG sites using the Sequenom EpiTyper, a matrix-assisted laser desorption ionization-time of flight mass spectrometry-based platform because of its CpG-dense promoter region and subsequent difficulty in using pyrosequencing methodology. These assays were designed to cover CpG sites at or near the CpG sites found in our previous study to be prognostic indicators of HNSCC.<sup>7</sup> All primer sets and PCR conditions are listed in Supplementary Table 1S, online only. Bisulfite single-plex PCR amplification was performed using FastStart Taq Polymerase (Roche Diagnostics, Indianapolis, IN) for *CCNA1*, and HotStar Taq Master Mix Kit (Qiagen) for all other genes, with a forward and reverse primer concentration of 0.2 mM and 30 ng of bisulfite-converted DNA. Fifteen microliters of each PCR product was combined with the respective sequencing primer and methylation analysis by pyrosequencing was conducted using the Pyromark MD System (Biotage, Charlotte, NC), in accord with the manufacturer's protocol, including single-strand binding protein (PyroGold reagents). Measurement of all samples for every methylation marker selected was not possible if there was insufficient quantity of total extracted DNA.

### Statistical analysis

Methylation values were calculated as means across all CpG sites of each gene. Locations of each CpG site and distance to transcription start site are listed in Supplementary Table 2S, online only. Site-specific and mean methylation from matched tissue specimens across time for *CCNA1*, *DCC*, and *CD1A* were compared using a non-parametric Wilcoxon-signed rank test because of skewed distributions. Methylation values for *NDN* were compared using a paired *t* test because of its Gaussian distribution. Pearson (*NDN*) and Spearman (*CCNA1*, *DCC*, and *CD1A*) correlation coefficients and 95% confidence intervals (CIs) were calculated for methylation across both timepoints. The difference in methylation between timepoints

TABLE 1. Percent methylation distribution for paired samples.

Gene	No. of patients	Initial biopsy	Rebiopsy/surgery	Difference*	<i>p</i> value <sup>†</sup>
<i>CCNA1</i> <sup>‡</sup>	86	23.5 (4.5–78)	24.8 (6.3–67.3)	0.9 (–31.3 to 53.3)	.56
<i>CD1A</i> <sup>‡</sup>	94	69.2 (21.8–95.9)	69.1 (21.4–91.1)	–0.2 (–28.2 to 36.3)	.66
<i>DCC</i> <sup>‡</sup>	96	33.1 (5.7–91.2)	32.2 (3.9–85.8)	–0.7 (–36.9 to 43.1)	.17
<i>NDN</i> <sup>‡</sup>	94	42.2 (34.9–51.2)	43.0 (36.3–52.3)	0.4 (–5.2 to 7.7)	.58 <sup>§</sup>

Abbreviations: *CCNA1*, cyclin A1; *CD1A*, cluster of differentiation 1a; *DCC*, deleted in colorectal carcinoma; *NDN*, necdin.

\* Rebiopsy or surgery-initial biopsy.

<sup>†</sup> *P* value for paired test.

<sup>‡</sup> Median (range).

<sup>§</sup> Parametric test.

was calculated for each gene and the differences and their absolute values were tested for correlation with the number of days between specimens. Correlation coefficients were also calculated subsetting by HPV status, smoking status, days between timepoints, and specimen type of the second sample. Differences in the amount of change in methylation values across subsets were tested using Wald tests from linear regression models and a correction for false discovery was applied to the *p* values to adjust for multiple comparisons of the various subgroup tests using *q* values described by Storey et al.<sup>26</sup> Multivariable analyses was conducted separately for each gene using a linear model to measure the association of days between sample collection and methylation differences, adjusting for HPV status, age, site, stage, and comorbidity status. Comorbidity data were abstracted from the medical record and graded by severity (none, mild, moderate, or severe) using the Adult Comorbidity Evaluation of 27 conditions organized by 12 systems.


## RESULTS

The study population consisted of 98 paired samples with the median time between the first and second tumor tissue specimens at 44 days (range, 8–156 days). Approximately 74% of the population was male. Tumor sites were primarily distributed across the larynx, oral cavity, and oropharynx (16%, 53%, and 29%, respectively) with 2% in the hypopharynx. Most patients were HPV-negative (69%). Only 16% were nonsmokers, whereas 46% were current smokers, or having quit within the past 12 months, and 38% were former smokers (quit more than 1 year ago). Mean age was 60 years (SD = 13 years). All genes showed a wide range of methylation levels across samples, as expected of epigenetic markers. There were no significant differences in overall methylation within paired specimens of *CCNA1*, *DCC*, and *CD1A*, or *NDN* (*p* values = .56, .17, .66, and 0.58, respectively; Table 1). The lack of significant differences in methylation across time persisted even when considering site-specific methylation within each gene (see Figure 1). Patterns of methylation across CpG sites within each gene were similar for both outside hospitals and University of Michigan samples, justifying the use of mean methylation across CpG sites as an appropriate measure to compare methylation across time.

All genes showed strong correlations between paired specimens across time. *CD1A* and *DCC* had identical correlation coefficients ( $\rho = 0.70$ ; 95% CI = 0.58–0.79 and

$\rho = 0.70$ ; 95% CI = 0.58–0.79, respectively; Figures 2c and 2d), whereas *CCNA1* and *NDN* had slightly lower correlations ( $\rho = 0.65$ ; 95% CI = 0.50–0.75 and  $\rho = 0.65$ ; 95% CI = 0.51–0.75, respectively; Figures 2a and 2b). There were no correlations between the differences in methylation between the 2 timepoints and the number of days between specimens for any gene (*CCNA1*:  $\rho = -0.04$ ; 95% CI = –0.25 to 0.17; *NDN*:  $\rho = -0.07$ ; 95% CI = –0.26 to 0.13; *CD1A*:  $\rho = 0.06$ ; 95% CI = –0.14 to 0.26; and *DCC*:  $\rho = -0.08$ ; 95% CI = –0.28 to 0.12). Additionally, there were no correlations between the absolute values of these differences and the number of days between specimens for any gene (*CCNA1*:  $\rho = 0.11$ ; 95% CI = –0.10 to 0.31; *NDN*:  $\rho = -0.16$ ; 95% CI = –0.35 to 0.04; *CD1A*:  $\rho = -0.008$ ; 95% CI = –0.21 to 0.19; and *DCC*:  $\rho = -0.04$ ; 95% CI = –0.24 to 0.16). Multivariable models run to assess the association of days between samples and methylation difference across time, adjusting for HPV status, age, site, stage, and comorbidity status, also showed no significant association between methylation differences and collection times (data not shown). These results demonstrate that methylation at both timepoints was strongly correlated and did not differ by the number of days between specimens.

As temporal changes in methylation levels may be associated with patient and tumor characteristics, correlations were also calculated separately by HPV status, smoking parameters, and whether the second specimen was from a biopsy or surgery resection; correlations were also calculated by the length of time between specimen sampling (Table 2). *CD1A* was most stable across time in HPV-negative patients ( $\rho = 0.77$ ; 95% CI = 0.65–0.85). Patients who had a biopsy at their second timepoint showed the most stable methylation at *NDN* ( $\rho = 0.77$ ; 95% CI = 0.53–0.89), whereas patients with a surgery resection specimen at the second timepoint showed the most stable methylation at *CD1A* and *DCC* ( $\rho = 0.74$ ; 95% CI = 0.61–0.83 and  $\rho = 0.75$ ; 95% CI = 0.62–0.84, respectively). Patients with shorter times between their tumor samples (0–44 days) showed the most stable methylation at *CCNA1* and *CD1A* ( $\rho = 0.71$ ; 95% CI = 0.52–0.83 and  $\rho = 0.74$ ; 95% CI = 0.58–0.85, respectively). Patients who had their second tissue sample beyond 44 days showed the most stable methylation at *DCC* ( $\rho = 0.72$ ; 95% CI = 0.55–0.83). Strong correlations across time were found for *CD1A* and *DCC* in former smokers ( $\rho = 0.81$ ; 95% CI = 0.65–0.90 and  $\rho = 0.79$ ; 95% CI = 0.62–0.88, respectively), *CCNA1* in current



smokers ( $\rho = 0.74$ ; 95% CI = 0.55–0.85), and *DCC* and *NDN* in never smokers ( $\rho = 0.84$ ; 95% CI = 0.59–0.94 and  $\rho = 0.74$ ; 95% CI = 0.39–0.90, respectively). To determine correlations accounting for intensity and duration of smoking, pack-years were also considered, using 20 pack-years as a cutoff.<sup>27</sup> Patients with <20 pack-years and with  $\geq 20$  pack-years showed the most stable methylation at *CD1A* ( $\rho = 0.78$ ; 95% CI = 0.57–0.89 and  $\rho = 0.73$ ; 95% CI = 0.57–0.84, respectively). None of the subset differences we observed proved statistically significant after  $p$  values were corrected for multiple comparisons, likely due to sample size.

### Probability of stable methylation across time

It is difficult to define methylation cutoffs that are biologically relevant. To compare consistency across time, we determined the proportion of specimens that fell within 10% and 20% of methylation at the first timepoint. Methylation was most consistent across time for *CCNA1* and *NDN*. Approximately 91% and 96% of patients, respectively, had methylation levels of these markers at the second time point within 20% of methylation at the first timepoint. *CD1A* and *DCC* methylation at the second timepoint was within 20% of methylation at the first timepoint for 85% and 79% of the patient population, respectively. This consistency persisted when restricting methylation change to 10%. Approximately 66% and 68% of patients

had methylation of *CCNA1* and *NDN* at the second timepoint within 10% of methylation at the first timepoint, respectively. The probability of *CD1A* and *DCC* methylation at the second timepoint staying within 10% of the first timepoint was 60% and 53%, respectively.

### DISCUSSION

These findings in patients with head and neck cancer demonstrate the stability of DNA methylation changes in tumor specimens from the time of biopsy to time of surgical treatment or second biopsy ranging from 8 to 156 elapsed days. To date, this is the first study to examine changes in methylation of specific genes across time and from different tumor samples within the same patients.

Correlations across time and by patient characteristic were positive and statistically significant, although the strength of correlations differed slightly based on patient characteristics, potentially because of underlying biological mechanisms associated with these genes. For example, we found that methylation of our genes was more strongly correlated across time in HPV-negative tumors, likely because of the fact that HPV-positive tumors tend to have more DNA methylation events in genic regions.<sup>8</sup> The strength of correlations was higher in specific genes when considering patient characteristics, indicating that a gene chosen for diagnostic purposes may depend on a patient's clinical profile.




TABLE 2. Correlations within subsets of population.

Parameter	No. of patients	<i>CCNA1</i>		No. of patients	<i>CD1A</i>		No. of patients	<i>DCC</i>		No. of patients	<i>NDN</i>	
		Rho*	(95% CI)		Rho*	(95% CI)		Rho*	(95% CI)		Rho*	(95% CI)
Second specimen type												
Biopsy	25	0.64	(0.33–0.83)	27	0.63	(0.33–0.81)	27	0.57	(0.24–0.78)	26	0.77	(0.54–0.89)
Surgery	61	0.64	(0.46–0.77)	67	0.74	(0.61–0.83)	69	0.75	(0.62–0.84)	68	0.56	(0.37–0.70)
HPV status												
HPV+	27	0.52	(0.17–0.75)	29	0.45	(0.10–0.70)	29	0.49	(0.15–0.73)	28	0.57	(0.25–0.78)
HPV-	59	0.52	(0.30–0.68)	65	0.77	(0.65–0.85)	67	0.60	(0.42–0.73)	66	0.58	(0.39–0.72)
Days between specimens <sup>†</sup>												
0–44	43	0.71	(0.52–0.83)	49	0.74	(0.58–0.85)	49	0.64	(0.44–0.78)	48	0.67	(0.48–0.80)
>44	43	0.52	(0.26–0.71)	45	0.68	(0.48–0.81)	47	0.72	(0.55–0.83)	46	0.65	(0.44–0.79)
Smoking status												
Current	39	0.74	(0.55–0.86)	44	0.67	(0.46–0.81)	44	0.48	(0.21–0.68)	44	0.59	(0.36–0.75)
Former	33	0.58	(0.30–0.77)	34	0.81	(0.65–0.90)	36	0.79	(0.62–0.88)	34	0.68	(0.44–0.83)
Never	14	0.64	(0.17–0.87)	16	0.49	(–0.01 to 0.79)	16	0.84	(0.59–0.94)	16	0.74	(0.39–0.90)
Pack-years <sup>‡</sup>												
<20	26	0.65	(0.35–0.83)	27	0.78	(0.57–0.89)	28	0.67	(0.40–0.83)	28	0.59	(0.28–0.79)
≥20	45	0.60	(0.37–0.76)	50	0.73	(0.57–0.84)	51	0.66	(0.47–0.79)	50	0.67	(0.48–0.80)

Abbreviations: *CCNA1*, cyclin A1; *CD1a*, cluster of differentiation 1a; *DCC*, deleted in colorectal carcinoma; *NDN*, necdin; 95% CI, 95% confidence interval; HPV, human papillomavirus.

\* Correlation coefficient.

<sup>†</sup> Cutoff based on median.

<sup>‡</sup> Cutoff based on Gillison et al.<sup>17</sup>

A limitation of this study was the variability of methylation within each gene. Because the differences observed between paired specimens were uncorrelated with length of time separating the specimens, they are instead likely because of heterogeneity within the tumors, measurement variability in the assay itself, measurements made across mixed cell populations, averages taken across several CpG sites in promoter regions, or intraindividual variability in methylation across time. It is important to note that although our biopsies came from a separate institution, the management of the biopsy material is fairly standardized across hospitals. The sample is placed in formalin immediately upon excision and eventually embedded in paraffin. There are many factors that may potentially affect methylation, the most significant being sampling error because of samples being taken from differing locations in the tumor (i.e., periphery for the biopsy and perhaps more central location for the resection). However, because minimal differences were noted in methylation between these 2 timepoints and locations, it is unlikely that differing institutions would be a significant variable. In addition, our findings showed no significant differences in paired distributions, relatively strong correlation coefficients as high as 0.84, and high probabilities of stable methylation within patients across time. These findings support the conclusion that when targeting epigenetic changes, alterations in gene methylation after initial biopsy likely reflect biologic changes rather than sampling errors. Additionally, these are issues that are likely to impact any clinical measurement, and, thus, these results represent a realistic assessment of the persistence of methylation levels.

The amount of methylation change needed to instigate a biological effect is currently unknown. Therefore, it is important that methylation levels remain relatively consistent across time when considered in a clinical setting. Here, we show high probabilities of *CCNA1* and *NDN* methylation to be within 10% and 20% of the first measurement. *CDIA* and *DCC* methylation had lower probabilities indicating that, in the tumor microenvironment, some genes are stably methylated while others are not, presumably to promote the tumorigenic phenotype.

Although stability of methylation of other specific genes could differ, our current findings are significant because these genes have been shown to be important in HNSCC.<sup>7,8</sup> We report *CCNA1* and *DCC* methylation levels similar to previous studies.<sup>16,19,28</sup> *CDIA* and *NDN* methylation has not been previously reported. The results of this study provide evidence for the stability over time of specific gene methylation measured in biopsy samples and supports the use of biopsy results as representative of the entire tumor, and as a potential prognostic indicator that could aid in defining personalized treatment.

## Acknowledgments

The following clinical coinvestigators of the University of Michigan Head and Neck Specialized Program of Research Excellence contributed to this work with patient enrolment, treatment, biospecimen collection, follow-up, and data collection: Carol Bradford; Thomas E. Carey, PhD; Douglas B. Chepeha, MD; Mark Prince, MD; Jeffrey Moyer, MD; Avraham Eisbruch, MD; Francis Worden, MD; Joseph I. Helman, MD; and Brent B. Ward, DDS, MD.

## REFERENCES

- Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis. *J Neurooncol* 2011;105:325–335.
- Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. *N Engl J Med* 2000;343:1350–1354.
- Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. *Clin Cancer Res* 2004;10:4420–4426.
- Agrelo R, Cheng WH, Setien F, et al. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. *Proc Natl Acad Sci U S A* 2006;103:8822–8827.
- Smith IM, Mydlarz WK, Mithani SK, Califano JA. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. *Int J Cancer* 2007;121:1724–1728.
- Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. *Oncol Rep* 2009;22:1519–1526.
- Colacino JA, Dolinoy DC, Duffy SA, et al. Comprehensive analysis of DNA methylation in head and neck squamous cell carcinoma indicates differences by survival and clinicopathologic characteristics. *PLoS One* 2013; 8:e54742.
- Sartor MA, Dolinoy DC, Jones TR, et al. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. *Epigenetics* 2011;6:777–787.
- Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. OncoPrint 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia* 2007;9:166–180.
- Asai T, Liu Y, Nimer SD. Necdin, a p53 target gene, in normal and cancer stem cells. *Oncotarget* 2013. [Epub ahead of print]
- De Faveri LE, Hurst CD, Platt FM, et al. Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer. *Br J Cancer* 2013;108:1368–1377.
- Haviland R, Eschrich S, Bloom G, et al. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer. *PLoS One* 2011;6:e24923.
- Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. *J Clin Oncol* 2006;24:778–789.
- Tan AC, Jimeno A, Lin SH, et al. Characterizing DNA methylation patterns in pancreatic cancer genome. *Mol Oncol* 2009;3:425–438.
- Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature* 2015;517: 576–582.
- Weiss D, Basel T, Sachse F, Braeuninger A, Rudack C. Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation. *Mol Carcinog* 2011;50:680–688.
- Gillison ML. Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers. *J Clin Oncol* 2006;24:5623–5625.
- Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. *J Clin Oncol* 2008;26:3128–3137.
- Carvalho AL, Chuang A, Jiang WW, et al. Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma. *Cancer Res* 2006; 66:9401–9407.
- Langevin SM, Butler RA, Eliot M, et al. Novel DNA methylation targets in oral rinse samples predict survival of patients with oral squamous cell carcinoma. *Oral Oncol* 2014;50:1072–1080.
- Arthur AE, Peterson KE, Shen J, et al. Diet and proinflammatory cytokine levels in head and neck squamous cell carcinoma. *Cancer* 2014;120:2704–2712.
- Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. *J Clin Oncol* 2008;26:3138–3146.
- Maxwell JH, Kumar B, Feng FY, et al. HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. *Head Neck* 2010;32:562–567.
- Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. *Clin Cancer Res* 2010;16:1226–1235.
- Walline HM, Komarck C, McHugh JB, et al. High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers:

- 
- comparison of multiple methods. *JAMA Otolaryngol Head Neck Surg* 2013;139:1320–1327.
26. Storey JD, Taylor JE, Siegmund D. Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach. *J R Stat Soc Series B Stat Methodol* 2004;66:187–205.
27. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. *J Natl Cancer Inst* 2008;100:407–420.
28. Rettori MM, de Carvalho AC, Longo AL, et al. TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors. *J Transl Med* 2013;11:316.